AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2484510
Drug: Selenate, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenate, 200 micrograms daily
Trial: 2484510
Drug: L-selenomethionine, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-selenomethionine, 200 micrograms daily
Trial: 2484510
Drug: High selenium
RxNorm normalized name: HIGH SELENIUM YEAST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High selenium yeast, 200 micrograms daily
Trial: 2484510
Drug: Inorganic selenium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inorganic selenium compounds (selenite, selenate)
Trial: 21995692
Drug: Simvastatin/Ezetimibe 10/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin/Ezetimibe 10/10 mg
Trial: 2465437
Drug: Ketanserin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (40 mg every 12 h)
Trial: 28330908
Drug: Dairy intervention
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dairy intervention (3 servings/d equivalent to ∼900 mg Ca/d)
Trial: 28330908
Drug: Control (usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (usual intake, achieving 1000 mg Ca/d)
Trial: 17526170
Drug: Modified Xiaoyao
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Xiaoyao Decoction (MXD) combining clomipramine 25‐50 mg/d
Trial: 17526170
Drug: Clomipramine 75‐225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine 75‐225 mg/d alone
Trial: 11981102
Drug: Intravenous dose-adjusted
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dose-adjusted UFH
Trial: 7882602
Drug: cilazapril 2.5
RxNorm normalized name: cilazapril 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cilazapril 2.5 mg/day
Trial: 3257670
Drug: Single-dose treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose treatment (trimethoprim, 320 mg and sulfamethoxazole, 1600 mg)
Trial: 7420563
Drug: 10-day treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day treatment
Trial: 3257670
Drug: Single-dose treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose treatment
Trial: 31359499
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg daily plus a four-drug regimen (amoxicillin, clarithromycin, bismuth, and esomeprazole) for 14 weeks
Trial: 27613357
Drug: Sildenafil 100
RxNorm normalized name: sildenafil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 100 mg oral dose prior to RAPN
Trial: 22079914
Drug: Microdermabrasion treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microdermabrasion treatment sessions (maximum 20 sessions over the course of a year)
Trial: 22079914
Drug: Microdermabrasion treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microdermabrasion treatment
Trial: 12111597
Drug: Clarithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (500 mg twice daily for 7 days)
Trial: 10594490
Drug: Twice a
RxNorm normalized name: Pataday Twice A Day Relief
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice a day placebo regimen
Trial: 9122001
Drug: TRH test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRH test (0.4 mg i.v.)
Trial: 9122001
Drug: TRH and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRH and TRH with naloxone (2 mg i.v.)
Trial: 22741259
Drug: Medicated thread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicated thread moxibustion of Zhuang medicine (group B)
Trial: 11593638
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no HBIG injection)
Trial: 419164
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dosages of psychotropic drugs (neuroleptics, antidepressants, anxiolytics, psychostimulants)
Trial: 19188877
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (Q6H lubrication and eye closure)
Trial: 19188877
Drug: Both eyes
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both eyes (control and treatment)
Trial: 15342805
Drug: Tamoxifen plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen plus radiation therapy
Trial: 8606523
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg talinolol
Trial: 9553680
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg talinolol
Trial: 9553680
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg talinolol (twice daily)
Trial: 8713783
Drug: Control (Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Heparin alone)
Trial: 21559284
Drug: Intravenous GH
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous GH bolus
Trial: 17304887
Drug: Ciclesonide, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclesonide, 200 microg once daily for 6 weeks
Trial: 15460498
Drug: Three-day pretreatment
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-day pretreatment with lansoprazole 30 mg twice daily
Trial: 10225769
Drug: LDL apheresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL apheresis fortnightly plus simvastatin 40 mg/day
Trial: 10225769
Drug: Colestipol 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colestipol 20 g plus simvastatin 40 mg/day
Trial: 3902375
Drug: Oral flupirtine
RxNorm normalized name: FLUPIRTINE
DrugBank: Flupirtine (DB06623)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral flupirtine maleate (100 to 200 mg)
Trial: 3902375
Drug: Oral pentazocine
RxNorm normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral pentazocine (50 to 100 mg)
Trial: 27435438
Drug: Intravenous oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous oxycodone (0.1 mg/kg) 10 minutes before surgery over 2 minutes
Trial: 20639026
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg serlopitant
Trial: 20639026
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg tolterodine
Trial: 16246964
Drug: Sildenafil (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (100 mg, n=19)
Trial: 19844249
Drug: Late initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Late initiation of estrogen therapy
Trial: 15933313
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate treatment in trial participants (Magpie Trial)
Trial: 10366994
Drug: clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clopidogrel 75 mg once daily for 11 days
Trial: 10366994
Drug: naproxen 250
RxNorm normalized name: naproxen 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen 250 mg b.i.d. for 7 days + placebo for 11 days
Trial: 10366994
Drug: naproxen 250
RxNorm normalized name: naproxen 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen 250 mg b.i.d. for 7 days + clopidogrel 75 mg once daily for 11 days
Trial: 25673206
Drug: Intra-amniotic injection
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-amniotic injection of ethacridine lactate (EL group)
Trial: 20074228
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of acetylsalicyclic acid (ASA), acetaminophen, and caffeine
Trial: 20074228
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with single substances (ASA, acetaminophen, or caffeine)
Trial: 16205558
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (sham injections)
Trial: 10611883
Drug: Naproxen 750
RxNorm normalized name: naproxen 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 750 mg per day
Trial: 799975
Drug: Indomethacin 75
RxNorm normalized name: indomethacin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 75 mg per day
Trial: 2328752
Drug: Enzyme potentiated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzyme potentiated desensitising vaccine (single injection in March)
Trial: 42333
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of chlorpheniramine and cimetidine
Trial: 26717366
Drug: Sunitinib (25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (25mg qd for 10 days between cycles) combined with docetaxel (40 mg) and cisplatin (50 mg) for 12 cycles (24 weeks) followed by maintenance vinorelbine (30mg TIW) until disease progression
Trial: 26717366
Drug: Sunitinib combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib combined with chemotherapy
Trial: 18949216
Drug: 60 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/kg PZQ + 6 mg/kg AM
Trial: 18949216
Drug: 60 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/kg PZQ + AM placebo
Trial: 18949216
Drug: 120 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg/kg PZQ + 6 mg/kg AM
Trial: 32007
Drug: Chlorothiazide twice
RxNorm normalized name: Chlorothiazide
DrugBank: Chlorothiazide (DB00880)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorothiazide twice a day plus atenolol, metoprolol, pindolol and propranolol in single daily doses
Trial: 32007
Drug: Each beta‐adrenoreceptor‐blocking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each beta‐adrenoreceptor‐blocking drug
Trial: 17938794
Drug: Bolus infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus infusion (BI) of rFVIIa (90 microg/kg every 2 hours during surgery through day 5, then every 4 hours for days 6-10)
Trial: 11780862
Drug: Repinotan (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repinotan (0.5 mg/day)
Trial: 11780862
Drug: Repinotan (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repinotan (1.25 mg/day)
Trial: 11780862
Drug: Repinotan (2.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repinotan (2.50 mg/day)
Trial: 7797214
Drug: Metoprolol (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (50-100 mg per day)
Trial: 3044068
Drug: High sucrose
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High sucrose diet (220 g of sucrose daily)
Trial: 3044068
Drug: Complex carbohydrate
RxNorm normalized name: Complex carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex carbohydrate (CHO) diet (less than 3 g of sucrose daily)
Trial: 3044068
Drug: High sucrose
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High sucrose diet (220 g of sucrose daily) in patients with preexisting higher triglyceridemia
Trial: 24341382
Drug: AZD8309 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD8309 (300 mg)
Trial: 21495995
Drug: Oral lymecycline
RxNorm normalized name: lymecycline
DrugBank: Lymecycline (DB00256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lymecycline 300 mg with adapalene 0.1%-BPO 2.5% (A/BPO)
Trial: 21495995
Drug: Oral lymecycline
RxNorm normalized name: lymecycline
DrugBank: Lymecycline (DB00256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lymecycline 300 mg with vehicle gel
Trial: 30121072
Drug: Intraoperative GDFT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative GDFT guided by PVI, administering fluid boluses of 3 ml/kg tetrastarch aiming at a PVI value below 10%.
Trial: 25722222
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin therapy with glargine
Trial: 25722222
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin therapy with detemir
Trial: 19828484
Drug: Normal magnesium
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal magnesium levels (<=1.0 mmol/l)
Trial: 17984189
Drug: Glutamine (Gln)
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine (Gln) supplementation (100 mg kg(‐1) body weight)
Trial: 17984189
Drug: Alanine (Ala)
RxNorm normalized name: Alanine
DrugBank: Alanine (DB00160)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alanine (Ala) supplementation (100 mg kg(‐1) body weight)
Trial: 1514487
Drug: Single-port infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-port infusion protocol
Trial: 6487499
Drug: Enprofylline at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enprofylline at plasma concentrations of 4.0 micrograms/ml
Trial: 6487499
Drug: Theophylline at
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline at plasma concentrations of 5.5 micrograms/ml
Trial: 6487499
Drug: Theophylline at
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline at plasma concentrations of 10.8 micrograms/ml
Trial: 6487499
Drug: Theophylline at
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline at plasma concentrations of 15.2 micrograms/ml
Trial: 6487499
Drug: Enprofylline (above
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enprofylline (above 2.9 micrograms/ml)
Trial: 6487499
Drug: Theophylline infusion
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline infusion
Trial: 29244746
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot juice (70 mL, 5.6 mmol NO₃‐)
Trial: 19364250
Drug: Subcutaneous apomorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous apomorphine co-administered with trimethobenzamide or domperidone premedication
Trial: 15024927
Drug: Unsupervised treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsupervised treatment with primaquine (14 doses provided upon enrollment)
Trial: 15960211
Drug: Diclofenac intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac intramuscular single dose
Trial: 15960211
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received morphine by Patient Controlled Analgesia (PCA)
Trial: 8739682
Drug: 0.5% timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% timolol solution given twice daily
Trial: 8739682
Drug: 0.5% timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% timolol in gel‐forming solution given once daily
Trial: 8739682
Drug: 0.5% timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% timolol solution
Trial: 8739682
Drug: 0.5% timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% timolol in gel‐forming solution
Trial: 1890650
Drug: B2 agonists
RxNorm normalized name: VITAMIN B2
DrugBank: Flavin mononucleotide (DB03247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B2 agonists kallidin
Trial: 1890650
Drug: B2 agonists
RxNorm normalized name: VITAMIN B2
DrugBank: Flavin mononucleotide (DB03247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B2 agonists bradykinin
Trial: 22162258
Drug: Nigella sativa
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa oil capsules 500 mg twice/day
Trial: 22162258
Drug: Placebo (starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (starch filled capsules)
Trial: 12127708
Drug: Cefaclor (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor (40 mg/kg/day in two doses for 5 days)
Trial: 12127708
Drug: Amoxycillin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (40 mg/kg/day in three doses for 10 days)
Trial: 21863679
Drug: Manually controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manually controlled infusion (MCI) of propofol with initial bolus 0.5 mg/kg and initial infusion rate 1.5 mg/kg/hr.
Trial: 21863679
Drug: Effective-site target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effective-site target controlled infusion (TCI) of propofol.
Trial: 21863679
Drug: Manually controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manually controlled infusion (MCI) of propofol.
Trial: 17564405
Drug: Inactive oral
RxNorm normalized name: activated charcoal Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive oral device
Trial: 7555937
Drug: Pull method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pull method with antibiotic prophylaxis (amoxycillin‐clavulanic acid 3 x 1.2 g i.v. over 24 hours); 37 patients
Trial: 7555937
Drug: Pull method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pull method without antibiotic prophylaxis; 34 patients
Trial: 7555937
Drug: Push method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Push method without antibiotic prophylaxis; 29 patients
Trial: 7555937
Drug: Pull method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pull method with antibiotic prophylaxis; 37 patients
Trial: 6803871
Drug: Propranolol (480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (480 mg daily)
Trial: 9260735
Drug: Nifedipine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (60 mg daily)
Trial: 6803871
Drug: Propranolol (480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (480 mg daily) during cold pressor test
Trial: 6803871
Drug: Propranolol (480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (480 mg daily) during mental arithmetic test
Trial: 19143915
Drug: Flexible-dose sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible-dose sildenafil (50 or 100 mg)
Trial: 12187064
Drug: Sequential methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sequential methotrexate and 5-fluorouracil scheduling, epirubicin and cisplatin (MFAP regimen)
Trial: 343250
Drug: Naloxone hydrochloride
RxNorm normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naloxone hydrochloride (up to 10 mg)
Trial: 30830540
Drug: Adjuvant dendritic
RxNorm normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant dendritic cell therapy
Trial: 30830540
Drug: Local treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local treatment with curative intent
Trial: 25715403
Drug: Systemic treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic treatment
Trial: 22987089
Drug: L-carnitine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine supplementation (2 g/d)
Trial: 11407998
Drug: Sibutramine 15
RxNorm normalized name: sibutramine 15 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine 15 mg
Trial: 12131259
Drug: Placebo (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (200 g.d‐1 dextrose)
Trial: 7588171
Drug: Clomipramine 50-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine 50-150 mg (mean daily dose 106 mg)
Trial: 2254102
Drug: Classical radiation
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classical radiation therapy (IC)
Trial: 29630433
Drug: Intensity-modulated radiotherapy
RxNorm normalized name: California intense cedar pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensity-modulated radiotherapy with concurrent systemic therapy
Trial: 15860246
Drug: 2.5 mg/day
RxNorm normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/day glipizide GITS
Trial: 11732515
Drug: Ketoprofen 25
RxNorm normalized name: ketoprofen 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 25 mg rectally with i.v. placebo
Trial: 11732515
Drug: Ketoprofen 25
RxNorm normalized name: ketoprofen 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 25 mg i.v. with rectal placebo
Trial: 1320919
Drug: Intravenous granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous granisetron 2 micrograms/kg
Trial: 1320919
Drug: Intravenous granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous granisetron 3 mg single-dose regimen (equivalent to 40 micrograms/kg in a 75 kg person)
Trial: 6468816
Drug: Propafenon (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenon (900 mg/day)